{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Non-Hodgkin+Lymphoma&page=3",
    "query": {
      "condition": "Recurrent Non-Hodgkin Lymphoma",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 1199,
    "total_pages": 120,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Non-Hodgkin+Lymphoma&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Non-Hodgkin+Lymphoma&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T18:28:42.231Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03991884",
      "title": "Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Recurrent B Lymphoblastic Lymphoma",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Refractory B Lymphoblastic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Inotuzumab Ozogamicin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2019-09-24",
      "completion_date": "2023-06-28",
      "has_results": false,
      "last_update_posted_date": "2023-07-06",
      "last_synced_at": "2026-10-05T18:28:42.231Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03991884"
    },
    {
      "nct_id": "NCT02998476",
      "title": "A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Parsaclisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2017-03-02",
      "completion_date": "2021-02-05",
      "has_results": true,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-10-05T18:28:42.231Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Tempe, Arizona + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Modesto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02998476"
    },
    {
      "nct_id": "NCT06386315",
      "title": "Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Indolent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Indolent B-Cell Non-Hodgkin Lymphoma",
        "Refractory Indolent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Indolent Non-Hodgkin Lymphoma",
        "Refractory Indolent Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Endoscopic Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Involved-site Radiation Therapy (3 Fractions)",
          "type": "RADIATION"
        },
        {
          "name": "Involved-site Radiation Therapy (12 Fractions)",
          "type": "RADIATION"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2024-05-15",
      "completion_date": "2027-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-10-05T18:28:42.231Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Albert Lea",
          "state": "Minnesota"
        },
        {
          "city": "Mankato",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06386315"
    },
    {
      "nct_id": "NCT00002485",
      "title": "Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Childhood Germ Cell Tumor",
        "Extragonadal Germ Cell Tumor",
        "Leukemia",
        "Liver Cancer",
        "Lymphoma",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Psychosocial Effects of Cancer and Its Treatment",
        "Sarcoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "psychosocial assessment and care",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 359,
      "start_date": "1992-02",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2014-02-14",
      "last_synced_at": "2026-10-05T18:28:42.231Z",
      "location_count": 26,
      "location_summary": "Sacramento, California • Gainesville, Florida • Miami, Florida + 23 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002485"
    },
    {
      "nct_id": "NCT00641381",
      "title": "Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "carmustine",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "10 Years to 60 Years"
      },
      "enrollment_count": 25,
      "start_date": "2000-05-10",
      "completion_date": "2026-02-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-10-05T18:28:42.231Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00641381"
    },
    {
      "nct_id": "NCT00182637",
      "title": "Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2004-07",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2020-08-03",
      "last_synced_at": "2026-10-05T18:28:42.231Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00182637"
    },
    {
      "nct_id": "NCT06004167",
      "title": "Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lymphoma, B-Cell",
        "Relapsed Cancer",
        "Refractory Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Mediastinal Large B-cell Lymphoma",
        "High-grade B-cell Lymphoma",
        "Follicular Lymphoma",
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Adaptive Bridging Radiation Therapy (ABRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2024-01-14",
      "completion_date": "2024-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-09",
      "last_synced_at": "2026-10-05T18:28:42.231Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06004167"
    },
    {
      "nct_id": "NCT00033267",
      "title": "CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2002-04",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2014-04-03",
      "last_synced_at": "2026-10-05T18:28:42.231Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00033267"
    },
    {
      "nct_id": "NCT01258998",
      "title": "Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Nasal Type Extranodal NK/T-cell Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "B-cell Adult Acute Lymphoblastic Leukemia",
        "B-cell Chronic Lymphocytic Leukemia",
        "Cutaneous B-cell Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Hepatosplenic T-cell Lymphoma",
        "Intraocular Lymphoma",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Noncutaneous Extranodal Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-cell Leukemia/Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Hairy Cell Leukemia",
        "Small Intestine Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "T-cell Adult Acute Lymphoblastic Leukemia",
        "T-cell Large Granular Lymphocyte Leukemia",
        "Testicular Lymphoma",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Akt inhibitor MK2206",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2010-12",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2020-11-04",
      "last_synced_at": "2026-10-05T18:28:42.231Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01258998"
    },
    {
      "nct_id": "NCT02303392",
      "title": "Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prolymphocytic Leukemia",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Selinexor",
          "type": "DRUG"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jennifer Woyach",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2015-06-09",
      "completion_date": "2022-04-18",
      "has_results": true,
      "last_update_posted_date": "2025-06-10",
      "last_synced_at": "2026-10-05T18:28:42.231Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02303392"
    }
  ]
}